Giant Biogene Holding Co., Ltd. (HKG:2367)

Market Cap	27.05B -60.3%
Revenue (ttm)	6.15B -12.9%
Net Income	1.93B -26.0%
EPS	1.82 -29.2%
Shares Out	1.06B
PE Ratio	14.03
Forward PE	11.33
Dividend	1.41 (5.35%)
Ex-Dividend Date	Jun 1, 2026

Volume	2,775,336
Open	25.72
Previous Close	25.84
Day's Range	25.34 - 25.72
52-Week Range	24.20 - 65.70
Beta	0.73
Analysts	Buy
Price Target	40.39 (+58.52%)
Earnings Date	Aug 18, 2026

About Giant Biogene Holding

Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People’s Republic of China. It offers functional skincare products, medical dressings and devices, and functional food products under the KOMFYMED, Collgene, Ke Yu, SKIGIN, and other brands. The company also develops and manufactures rare ginsenosides technology-based functional food products. In addition, it provides aesthetic services. The company was founded ...

• Industry: Household & Personal Products
• Sector: Consumer Staples
• Founded: 2000
• Employees: 2,319
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2367

Financial Performance

In 2025, Giant Biogene Holding's revenue was 5.52 billion, a decrease of -0.37% compared to the previous year's 5.54 billion. Earnings were 1.91 billion, a decrease of -7.15%.

Financial numbers in CNY

Analyst Summary

According to 18 analysts, the average rating for 2367 stock is "Buy." The 12-month stock price target is $40.39, which is an increase of 58.52% from the latest price.

Price Target

$40.39

(58.52% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error